



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Freyne, Eddy J. et al.

Serial No.: 10/596,512

Art Unit: 1624

Filed

: December 15, 2004

Examiner:

For

: PYRIDO-AND PYRIMIDOPYRIMIDINE DERIVATIVES

AS ANTI-PROFILERATIVE AGENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 30, 2006

Alana G. Kriegsman
(Name of applicant, assignee, or Registered Representative)

/Alana G. Kriegsman/

(Signature)

October 30, 2006

(Date of Signature)

Mail Stop: Patent Application Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

. Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

 \boxtimes In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with | the first or | Second After Final Submission, therefore: П Statement in Accordance with \$1.97(e) (attached); or П Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is

accompanied by one of:

Statement in Accordance with §1.97(e)
Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in \$1.17(p).
☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of §180.00 as set forth in §1.17(p).
\boxtimes Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO 1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
☐ Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98

(a)(2).

 \boxtimes There are no listed references which are not in the English language. The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2170USPCT/AGK. This form is submitted in triplicate. Respectfully submitted, /Alana G. Kriegsman/ Alana G. Kriegsman Reg. No. 41,747 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1495 DATED: October 30, 2006



PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Application Number 10/596,512 12/15/2004 Filing Date First Named Inventor Eddy J. Freyne Group Art Unit 1624 Examiner Name Attorney Docket Number PRD2170USPCT

U.S. PATENT DOCUMENTS U.S. Patent Document													
Examiner Initials		U.S. Patent Document			Date of Publication	Pages, Columns, Lines,							
	Cite No.1									Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy
_					-								
			-										

FOREIGN PATENT DOCUMENTS Foreign Patent Document ages, Columns, Lin of Cited Document Name of Patentee or where relevant passages or relevant Examiner Cite mm-dd-vvvv Applicant of Cited Document figures appear Initials Number⁴ KindCode⁵ wο 95/19774 A1 07-27-1995 Warner-Lambert Company 96/07657 03-14-1996 Α1 Dr. Karl Thomae GMBH 97/32880 Dr. Karl Thomae GMRH 09-12-1997 wo Δ1

Noble Jarrell 03/20/2009 Signature //NODIE Jdffell/ Considered U3/20/2009

"EXAMINER: Initial if reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), a For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. a Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Officer, Washington, D. 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (08-00)
Approved for use through 19/31/2002, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

se as many sheets as necess Sheet 2 of 2

a collection of information unless it displays	
Application Number	10/596,512
Filing Date	12/15/2004
First Named Inventor	Eddy J. Freyne
Group Art Unit	1624
Examiner Name	
Attorney Docket Number	PRD2170USPCT

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
nitials*	No.1	publisher city and/or country where published	
THE COLO	110.	BROWN et al., "High Throughput Screening", 1997, editors: Devlin, John P., Publishers: Dekker, New York, N.Y., pages	
		317-328.	
		BURKE, Terrence R. Jr., "Protein-tyrosine Kinase Inhibitors", <u>Drugs of The Future</u> , 1992, pages 119-131, Vol. 17, No. 2.	
		DAVIES et al., "Specificity and Mechanism of Action of Some Commonly Used Protein Kinase Inhibitors", <u>Biochemical</u> Society, 2000, pages 95-105, Vol. 351.	
		DELIA, Thomas, "Fused Pyrimidines, Part Four, Miscellaneous Fused Pyrimidines: Chapter VI-Pyrimidotriazines.", Heterocyclic Compounds, John Wiley & Sons, Inc., Interscience Publications, pages 261-304, 1 9 9 1	
		DRUKER et al., "Lessons Learned From The Development of An Abi Tyrosine Kinase Inhibitor For Chronic Myalogannus Laukemia", The Journal of Clinical Investigation, January 2000, pages 3-7, Vol. 5, No. 1.	
		ELDER et al., "Overexpression of transforming growth factor alpha in psoriatic epidermis", <u>Science</u> , 1989, pages 811-814, Vol. 243.	
		GENNARO et al. Remington's Pharmaceutical Sciences, 19 th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical preparations and their Manufacture.	
	i	MORIN, Michael J., "From Oncogene to Drug: Development of Small Molecule Tyrosine Kinase Inhibitors as Anti-tumor and Anti-angiogenic Agents", Oncogene, 2000, pages 6574-6583, Vol. 19.	
		NAGAMATSU et al., "Sytheses of 3-Substituted 1-Methyl-6-Phenylpyrimido[5.4-e]-1.2,4-triazino-5,7(11/,6-fr)-diones (6- Phenyl Analogs of Toxollavin) and Their 4-Oxides, and Evaluation of Antimicrobial Activity of Toxollavins and Their Analogs," Chem Pherm Bull. 1993, pages 362-368, Vol 41, No. 2.	
		NAGAMATSU et al., "General Syntheses of 1-Alkytloxoflavin and 8-Alkytlervenulin Derivatives of Biological Significance by The Regioselective Alytation of Reumycin Derivatives And The Rates of Transalkytation From 1-Alkytloxoflavins Into By Italians, "J. Chem. Soc. Perkin Trans. 1, 2001, pages 130-137.	
		SHAWVER et al., "Smart Drugs: Tyrosine Kinase Inhibitors In Cancer Therapy", Cancer Cells, March 2002, pages 117- 123, Vol 1.	
	-		

Examiner /Noble Jarrell/	Date 03/20/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Barden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary deponding upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patient and Trademark Office, Weahington, O.C. 2023.1. DO NOT SEND FEES OR COMMETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioned for Patients, F.O. BOX 1430, Address

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



SUBMISSION UNDER MPEP 609 D

Application Number 10/596,512
Fiting Date 12/15/2004
First Named Inventor Eddy J. Freyne
Group Art Unit 1624
Examiner Name PRD2470USPCT

Page 1 of 1

Page 1 of 1					
	U.S. PA				
		U.S. Patent Docum	nent		
Cite No.1	Name of Patentee or Applicant of Cited Document	Number (if known)		Pages, Columns, Lines, where relevant passages or relevant figures appear	
-		-			
-		4 :- :-	- 134 2		
		U.S. PA Name of Patentee or Applicant of Cited Document	U.S. PATENT DOCUMENTS Cite Name of Patentee or Applicant of Cited Document Number Number	U.S. PATENT DOCUMENTS U.S. Patent Document U.S. Patent Document U.S. Patent Document Kind Code ²	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Foreign Pa	Number ⁴ K	indCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁰
_			<u> </u>				
		OTHER PRIOR ART - I					
Examiner 's Initials*	's No.' volume-issue number(s), publisher, city and/or country where published					g, etc.), date, page(s),	T2
		PCT Intl. Search Report, PCT/EP2004	/053501, Apri	128, 2005.			

Examiner	/Noble Jarrell/	Date	03/20/2009	
Signature	THE COUNTY OF TH	Considered	OGIEGIEGO	